Drug intelligence / Profile preview

LB-05

Development stage: Preclinical
Lead developer: LexBio Therapeutics
Modality: Small Molecules

Overview

LB-05 is a small molecule therapeutic currently in the lead optimization stage of preclinical development by LexBio Therapeutics. It is being investigated for the treatment of solid tumors. As of the current pipeline status, the specific molecular target and mechanism of action remain undisclosed by the developer. The program represents part of LexBio's early-stage oncology portfolio focused on identifying novel small molecule inhibitors for cancer therapy.

Beyond the preview

Go deeper on LB-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB-05.

Explore the full profile